Empower Clinics Provides Corporate Update

SEATTLE,  WA:  January  17,  2019  –  EMPOWER  CLINICS  INC.  (CSE:  EPW)  (Frankfurt 8EC)  (“Empower”  or  the  “Company”)  today  provided  a  corporate  update  on  operations and changes to its board of directors

The  Company  is  pleased  to  announce  its  first  production  run  of  Sollievo  CBD  lotion  has commenced selling in two test markets – Portland, OR and Seattle, WA. Initial product sales are direct to market both in Empower clinics located in the test markets and through other practitioners, such as chiropractors, health & fitness clubs and elder care facilities.

HOW  IT  WORKS:  All  Sollievo  products  are  powered  by  99%  pure  hemp  CBD  isolate  and proprietary  terpene  blends.  CBD  (cannabidiol)  is  a  non-psychoactive  molecule  found  in hemp and cannabis plants. After multiple stages of refinement, CBD is purified into crystals (isolate) and other compounds like chlorophyll are removed.

Every Sollievo product uses CBD crystals combined with naturally derived terpene blends to address  specific  everyday  ailments  like  chronic  pain,  insomnia,  digestion  issues,  and anxiety.  The  blends  are  designed  by  top  scientists  in  the  hemp  and  cannabis  industry  to address the most common qualifying conditions of Empower Clinics patients and consumers.

Empower Clinics’ doctors advised a team of chemists, biologists and product designers in creating products that will never intoxicate you or leave you with a hangover. Currently, the Empower product development team has created numerous proprietary product blends and categories,  in  various  stages  of  product  analysis,  packaging  and  roll-out,  including  CBD lotions, tinctures, spectrum oils, capsules, lozenges, patches and an eDrink.

“The  passing  of  the  US$867  billion  Agriculture  Improvement  Act  (the  Farm  Bill)  has legalized hemp and hemp based products. This has created a massive opportunity for the production and sales of a variety of CBD based products that can provide genuine help and effective relief to millions of people suffering from a variety of serious qualifying conditions,” said  Steven  McAuley,  Empower  Chairman  &  CEO.  He  further  states,  “Recent  reports  and studies indicate the approval of this bill could create a US$20 billion industry by 2022.”

The Company would also like to announce the resignation of Mr. Dan Ballister as a director of Empower and thanks him for his service and support of the Company. The Company also announces  the  appointment  of  Ms.  Emily  Davis  as  a  director  of  the  Company.  Ms.  Davis brings extensive corporate and public company experience and will support the Company in this role as it continues to identify new candidates for its board of directors,

ABOUT EMPOWER

Empower is a leading owner/operator of a network of physician-staffed clinics focused on helping  patients  improve  and  protect  their  health  through  innovative  uses  of  medical cannabis. Treatment solutions are focused on education, data and efficacy in combination with other modalities to support patients with serious qualifying conditions, such as chronic pain,  PTSD,  sleep  disorders,  opioid  dependency,  epilepsy  and  more.  It  is  expected  that Empower’s  proprietary  product  line  “Sollievo”  will  offer  patients  a  variety  of  delivery methods of doctor recommended medical cannabis product options in its clinics, online and at major retailers. With over 120,000 patients, an expanding clinic footprint, a focus on new technologies,  including  tele-medicine  and  an  expanded  product  development  strategy, Empower  believes  it  is  positioned  to  be  a  market-leading  service  provider  for  complex patient requirements in 2019 and beyond.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley

Chief Executive Officer

CONTACTS:

 

Investors:

Steve Low

Boom Capital Markets steve@boomcapitalmarkets.com

647-620-5101

FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” as contemplated  by  applicable  Canadian  securities  law.  Forward-looking  statements  are  frequently characterized  by  words  such  as  “plans”,  “continues”,  “expects”,  “projects”,  “intends”,  “believes”, “anticipates”,   “estimates”,   “may”,   “will”,   “potential”,   “proposed”   and   other   similar   words,   or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include, but are not limited to, statements regarding: the expected  availability of the Company’s  clinics  and  products;  the  expected  benefits  of  the  Company’s  products  and  that  the Company is positioned to be a market-leading service provider for complex patient requirements in 2019   and   beyond.  Such   statements   are   only   a   projection   based   on   assumptions   known   to management at this time, and are subject to risks and uncertainties that may cause actual results, performance  or  developments  to  differ  materially  from  those  contained  in  the  forward-looking statements,  including:  that  the  Company’s  products  may  not  work  as  expected;  that  legislative changes may have an adverse affect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.